Covid-19: NAFDAC Approves Chloroquine Production For Clinical Trial

The National Agency for Food and Drug Administration and Control, NAFDAC, has approved the production of chloroquine for clinical trials in the search for a cure for Coronavirus – COVID19.

The Director-General of NAFDAC made the announcement on Friday at the agency’s headquarters in Lagos, that NAFDAC is not approving Chloroquine for the treatment of COVID-19 but for clinical trials to find treatment for the virus.

“NAFDAC is not approving Chloroquine as a product that has can be used for Coronavirus because there is no submission to us for registration but because it is under clinical trials, NAFDAC approves medicines meant for clinical trials.

“Therefore the medicine is being approved just for the clinical trials,” Adeyeye said.

She, therefore, called on experts and researchers that are interested in doing a clinical trial on Chloroquine to approach approved outlets.

“Right now, we have asked one company to make a batch of Chloroquine for the purpose of the clinical trial,” Adeyeye added.

An FDA spokesperson said the drug, Chloroquine had not been approved for use in Covid-19 patients for the treatment of Coronavirus. However, U.S. doctors are legally able to prescribe a drug for any illness or condition they think is medically appropriate.